human urokinase Search Results


91
Assaypro assaymax human urokinase upa elisa kit
Assaymax Human Urokinase Upa Elisa Kit, supplied by Assaypro, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+Urokinase+(uPA)+AssayMax+ELISA+Kit/pmc04271208-220-28-34
Average 91 stars, based on 1 article reviews
assaymax human urokinase upa elisa kit - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

95
R&D Systems recombinant urokinase type plg activator
Recombinant Urokinase Type Plg Activator, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Recombinant+Human+u-Plasminogen+Activator%2FUrokinase%2C+CF/pmc04451130-139-27-32
Average 95 stars, based on 1 article reviews
recombinant urokinase type plg activator - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

94
R&D Systems human upa quantikine elisa kit
Human Upa Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+u-Plasminogen+Activator%2FUrokinase+Quantikine+ELISA/pmc12517313-153-10-15
Average 94 stars, based on 1 article reviews
human upa quantikine elisa kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
R&D Systems plau
Plau, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Recombinant+Human+u-Plasminogen+Activator%2FUrokinase%2C+CF/pm33752330-52-55-74
Average 93 stars, based on 1 article reviews
plau - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

95
MedChemExpress edta free proteinase inhibitor cocktails
Edta Free Proteinase Inhibitor Cocktails, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Serpin+B2%2C+Human/pmc12606951-69-19-23
Average 95 stars, based on 1 article reviews
edta free proteinase inhibitor cocktails - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

93
MedChemExpress urokinase type plasminogen activator upa
Urokinase Type Plasminogen Activator Upa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/PLAU%2FuPA%2C+Human/pmc12432381-38-0-5
Average 93 stars, based on 1 article reviews
urokinase type plasminogen activator upa - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
R&D Systems human urokinase plasminogen activator
Human Urokinase Plasminogen Activator, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+u-Plasminogen+Activator%2FUrokinase+DuoSet+ELISA/bio_rxiv__2020__08__03__235648-157-10-22
Average 93 stars, based on 1 article reviews
human urokinase plasminogen activator - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Cusabio e04751h
E04751h, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+urokinase+plasminogen+activator%2CuPA+ELISA+kit/bio_rxiv__2024__09__25__615051-60-25-26
Average 93 stars, based on 1 article reviews
e04751h - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
R&D Systems human upa quantikine elisa
Human Upa Quantikine Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+u-Plasminogen+Activator%2FUrokinase+Quantikine+ELISA/ppr0411137-108-12-16
Average 93 stars, based on 1 article reviews
human upa quantikine elisa - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
R&D Systems urokinase plasminogen activator
FIGURE 5 Inhibition of Notch1 expression decreases the production of CCL2, CXCL16, uPA, and uPAR. A, The expression of CCL2 protein was significantly inhibited in Notch1 shRNA‐transfected cells. B, The expression of CXCL16 in CNE2 cells was decreased by more than half in Notch1 shRNA‐transfected cells compared with the control cells. In CNE1 cells, knockdown of Notch1 expression also led to a decrease of CXCL16, but the result was not significantly different. C, The expression of the uPAR protein was markedly inhibited in Notch1 shRNA‐transfected cells. D, Knockdown of Notch1 decreased uPA expression by about two‐fold. Columns, mean of triplicate assays; bars, SEM. * and ** represent P < .05, and P < .01, respectively, indicates a significant difference compared with the EV control. All the data are from at least three independent experiments. EV, empty vector; uPAR, urokinase <t>plasminogen</t> activator receptor
Urokinase Plasminogen Activator, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+u-Plasminogen+Activator+(uPA)%2F+Urokinase+Catalytic+Domain+Antibody/pm31270884-22-14-29
Average 93 stars, based on 1 article reviews
urokinase plasminogen activator - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
Elabscience Biotechnology human fibroblast growth factor 23 elisa kit
FIGURE 5 Inhibition of Notch1 expression decreases the production of CCL2, CXCL16, uPA, and uPAR. A, The expression of CCL2 protein was significantly inhibited in Notch1 shRNA‐transfected cells. B, The expression of CXCL16 in CNE2 cells was decreased by more than half in Notch1 shRNA‐transfected cells compared with the control cells. In CNE1 cells, knockdown of Notch1 expression also led to a decrease of CXCL16, but the result was not significantly different. C, The expression of the uPAR protein was markedly inhibited in Notch1 shRNA‐transfected cells. D, Knockdown of Notch1 decreased uPA expression by about two‐fold. Columns, mean of triplicate assays; bars, SEM. * and ** represent P < .05, and P < .01, respectively, indicates a significant difference compared with the EV control. All the data are from at least three independent experiments. EV, empty vector; uPAR, urokinase <t>plasminogen</t> activator receptor
Human Fibroblast Growth Factor 23 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+suPAR+(Soluble+Urokinase-type+Plasminogen+Activator+Receptor)+ELISA+Kit/pmc13088700-282-8-7
Average 94 stars, based on 1 article reviews
human fibroblast growth factor 23 elisa kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
R&D Systems urokinase type plasminogen activator
YYB-101 treatment impedes tumor growth in vivo and downregulates important cellular molecular effectors. (A) Kaplan–Meier survival curves and representative boxplot of vehicle vs YYB-101-treated (5 mpk, 20 mpk) groups in BALB/c nude mice. P-values were calculated using the log-rank test for survival curve and Student’s t-test for boxplot. (B) Representative immunohistochemical images of p-MET, p-GAB1, p-FAK, MMP2, <t>uPA/plasminogen,</t> and Ki-67 stainings. Scale bars: p-MET, p-GAB1, p-FAK, MMP2, and uPA/plasminogen, 200 μm; Ki-67, 100 μm.
Urokinase Type Plasminogen Activator, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+urokinase/Human+u-Plasminogen+Activator+(uPA)%2FUrokinase+Antibody/pmc06374764-118-33-38
Average 94 stars, based on 1 article reviews
urokinase type plasminogen activator - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


FIGURE 5 Inhibition of Notch1 expression decreases the production of CCL2, CXCL16, uPA, and uPAR. A, The expression of CCL2 protein was significantly inhibited in Notch1 shRNA‐transfected cells. B, The expression of CXCL16 in CNE2 cells was decreased by more than half in Notch1 shRNA‐transfected cells compared with the control cells. In CNE1 cells, knockdown of Notch1 expression also led to a decrease of CXCL16, but the result was not significantly different. C, The expression of the uPAR protein was markedly inhibited in Notch1 shRNA‐transfected cells. D, Knockdown of Notch1 decreased uPA expression by about two‐fold. Columns, mean of triplicate assays; bars, SEM. * and ** represent P < .05, and P < .01, respectively, indicates a significant difference compared with the EV control. All the data are from at least three independent experiments. EV, empty vector; uPAR, urokinase plasminogen activator receptor

Journal: Molecular carcinogenesis

Article Title: Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA.

doi: 10.1002/mc.23082

Figure Lengend Snippet: FIGURE 5 Inhibition of Notch1 expression decreases the production of CCL2, CXCL16, uPA, and uPAR. A, The expression of CCL2 protein was significantly inhibited in Notch1 shRNA‐transfected cells. B, The expression of CXCL16 in CNE2 cells was decreased by more than half in Notch1 shRNA‐transfected cells compared with the control cells. In CNE1 cells, knockdown of Notch1 expression also led to a decrease of CXCL16, but the result was not significantly different. C, The expression of the uPAR protein was markedly inhibited in Notch1 shRNA‐transfected cells. D, Knockdown of Notch1 decreased uPA expression by about two‐fold. Columns, mean of triplicate assays; bars, SEM. * and ** represent P < .05, and P < .01, respectively, indicates a significant difference compared with the EV control. All the data are from at least three independent experiments. EV, empty vector; uPAR, urokinase plasminogen activator receptor

Article Snippet: Anti‐human monocyte chemoattractant protein 1 (MCP‐1/CCL2, #MAB279), C‐X‐C motif chemokine ligand 16 (CXCL16, #MAB976), urokinase plasminogen activator (uPA; #MAB1310), and uPA receptor (uPAR; #MAB807) monoclonal antibodies were purchased from R&D Systems (Minneapolis, MN).

Techniques: Inhibition, Expressing, shRNA, Transfection, Control, Knockdown, Plasmid Preparation

FIGURE 6 uPA acts as a key mediator in Notch1‐induced NPC cell proliferation and invasion. A, The scatterplot shows that uPA gene was highly expressed in NPC tissues by Human Genome U133 Plus 2.0 Array.34 B, The knockdown efficiency of uPA in CNE1 cells, compared with EV control cells, was determined by qPCR. C, CNE1 cell proliferation was examined by the MTS assay. D, uPA‐shRNA‐transfected cells resulted in the significant upregulation of E‐cadherin protein expression and a reduction in vimentin expression. Cyclin D and cyclin E expression were markedly decreased in uPA knockdown cells. E, uPA‐shRNA‐transfected cells (left panel) resulted in the low penetration of cells through the Matrigel‐coated membrane, compared with control cells. Invasive Index (%) was calculated (right panel) according to the manufacturer's instructions. The data are from three independent experiments. Columns, mean of triplicate assays; bars, SEM. EV, empty vector; NPC, nasopharyngeal carcinoma; shRNA, short hairpin RNA; uPA, urokinase plasminogen activator. *P < .05, and **P < .01, respectively, indicates a significant difference compared with the EV control [Color figure can be viewed at wileyonlinelibrary.com]

Journal: Molecular carcinogenesis

Article Title: Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA.

doi: 10.1002/mc.23082

Figure Lengend Snippet: FIGURE 6 uPA acts as a key mediator in Notch1‐induced NPC cell proliferation and invasion. A, The scatterplot shows that uPA gene was highly expressed in NPC tissues by Human Genome U133 Plus 2.0 Array.34 B, The knockdown efficiency of uPA in CNE1 cells, compared with EV control cells, was determined by qPCR. C, CNE1 cell proliferation was examined by the MTS assay. D, uPA‐shRNA‐transfected cells resulted in the significant upregulation of E‐cadherin protein expression and a reduction in vimentin expression. Cyclin D and cyclin E expression were markedly decreased in uPA knockdown cells. E, uPA‐shRNA‐transfected cells (left panel) resulted in the low penetration of cells through the Matrigel‐coated membrane, compared with control cells. Invasive Index (%) was calculated (right panel) according to the manufacturer's instructions. The data are from three independent experiments. Columns, mean of triplicate assays; bars, SEM. EV, empty vector; NPC, nasopharyngeal carcinoma; shRNA, short hairpin RNA; uPA, urokinase plasminogen activator. *P < .05, and **P < .01, respectively, indicates a significant difference compared with the EV control [Color figure can be viewed at wileyonlinelibrary.com]

Article Snippet: Anti‐human monocyte chemoattractant protein 1 (MCP‐1/CCL2, #MAB279), C‐X‐C motif chemokine ligand 16 (CXCL16, #MAB976), urokinase plasminogen activator (uPA; #MAB1310), and uPA receptor (uPAR; #MAB807) monoclonal antibodies were purchased from R&D Systems (Minneapolis, MN).

Techniques: Knockdown, Control, MTS Assay, shRNA, Transfection, Expressing, Membrane, Plasmid Preparation

YYB-101 treatment impedes tumor growth in vivo and downregulates important cellular molecular effectors. (A) Kaplan–Meier survival curves and representative boxplot of vehicle vs YYB-101-treated (5 mpk, 20 mpk) groups in BALB/c nude mice. P-values were calculated using the log-rank test for survival curve and Student’s t-test for boxplot. (B) Representative immunohistochemical images of p-MET, p-GAB1, p-FAK, MMP2, uPA/plasminogen, and Ki-67 stainings. Scale bars: p-MET, p-GAB1, p-FAK, MMP2, and uPA/plasminogen, 200 μm; Ki-67, 100 μm.

Journal: Neuro-Oncology

Article Title: Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma

doi: 10.1093/neuonc/noy105

Figure Lengend Snippet: YYB-101 treatment impedes tumor growth in vivo and downregulates important cellular molecular effectors. (A) Kaplan–Meier survival curves and representative boxplot of vehicle vs YYB-101-treated (5 mpk, 20 mpk) groups in BALB/c nude mice. P-values were calculated using the log-rank test for survival curve and Student’s t-test for boxplot. (B) Representative immunohistochemical images of p-MET, p-GAB1, p-FAK, MMP2, uPA/plasminogen, and Ki-67 stainings. Scale bars: p-MET, p-GAB1, p-FAK, MMP2, and uPA/plasminogen, 200 μm; Ki-67, 100 μm.

Article Snippet: Tissue sections of paraffin-embedded specimens were stained with the following primary antibodies: p-MET (Y1234/1235) (E9P0077, Enogene), p-GAB1 (Y307) (3234p, Cell Signaling), p‒focal adhesion kinase (FAK) (Y397) (ab4803, Abcam), MMP2 (6E3F8) (ab86607, Abcam), and urokinase-type plasminogen activator (uPA)/urokinase (AF1310, R&D system).

Techniques: In Vivo, Immunohistochemical staining